Aβ 1-42 (266)


Back to the Top

Clonality: monoclonal
Host: Mouse
Methods: ELISA
Source: amyloidβ 266
(P Seubert,
Elan Pharmaceuticals, South San Francisco, CA, Paper)
Britschgi, 2009
Schroeter, 2008
Shankar, 2008
Roberson, 2007
DeMatos, 2001
Reacts in: Human, Mouse
reference:<br />Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, David D, Sinha S, Schlossmacher M, y J, Swindlehurst, C, Nature London 359, 325-327, l992


immunogen = synthetic peptide, central domain 13-28 of Amyloid-beta 1-42 (epitope at 16-23)



Comments / Questions

Make a comment or submit a question

To make a comment you must login or register.

Comments on this content

No Available Comments


Paper Citations

  1. . Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. PubMed.
  2. . Immunotherapy reduces vascular amyloid-beta in PDAPP mice. J Neurosci. 2008 Jul 2;28(27):6787-93. PubMed.
  3. . Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med. 2008 Aug;14(8):837-42. PubMed.
  4. . Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007 May 4;316(5825):750-4. PubMed.
  5. . Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8850-5. PubMed.

External Citations

  1. Paper

Further Reading


  1. ALS: T Cells Step Up
  2. Uppsala: Immunotherapy and Biomarkers Take Center Stage
  3. The Well-Tempered Immune System: Taming Microglia to Fight AD
  4. Parkinson's Omnibus—Vaccination, New Rat Model, and More